Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study

Article Oncology

Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents

K. Fizazi et al.

ANNALS OF ONCOLOGY (2023)

Article Oncology

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)

Silke Gillessen et al.

Summary: Darolutamide maintenance after successful taxane chemotherapy shows promising efficacy and safety in patients with metastatic castration-resistant prostate cancer (mCRPC).

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N. Chi et al.

Summary: This study investigated the efficacy of niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC and HRR gene alterations. The results showed that the combination therapy significantly prolonged radiographic progression-free survival compared to abiraterone acetate plus prednisone alone. The treatment was well tolerated with manageable adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Matthew R. Smith et al.

Summary: Darolutamide, in combination with androgen-deprivation therapy and docetaxel, significantly increased overall survival among patients with metastatic hormone-sensitive prostate cancer compared to placebo plus androgen-deprivation therapy and docetaxel. The addition of darolutamide also led to improvement in secondary end points without notable differences in adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design

Karim Fizazi et al.

Summary: Combining androgen deprivation therapy, docetaxel, and abiraterone in de novo metastatic castration-sensitive prostate cancer improved overall survival and radiographic progression-free survival with a modest increase in toxicity, mostly hypertension.

LANCET (2022)

添加到收藏夹

Article Urology & Nephrology

2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)

Fred Saad et al.

Summary: This document was produced by conducting a MEDLINE search of the English language and conference proceedings to provide expert opinions to aid in patient management where Level 1 evidence is lacking. The levels of evidence and grades of recommendation utilize the ICUD/WHO modified Oxford Center for Evidence-Based Medicine grading system, with the strength of each recommendation represented as STRONG or WEAK based on a modified GRADE methodology.

CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2022)

添加到收藏夹

Article Urology & Nephrology

2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)

Fred Saad et al.

Summary: This document utilizes MEDLINE search of the English language and conference proceedings to provide expert opinion to aid in patient management. It employs the International Consultation on Urologic Disease (ICUD)/ WHO modified Oxford Center for Evidence-Based Medicine grading system. The strength of each recommendation is represented by STRONG or WEAK.

CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2022)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Meeting Abstract Oncology

Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.

Susan Halabi et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

Prostate cancer

Shahneen Sandhu et al.

Summary: Management of prostate cancer is rapidly evolving with advances in understanding the genomic landscape, improved imaging methods, and personalised therapeutics targeting DNA repair pathways. The therapeutic framework for metastatic disease has shifted, with oligometastatic disease being evaluated for metastatic-directed therapies, and novel androgen pathway inhibitors showing significant survival benefits as first-line therapy for metastatic disease. Emerging research into molecular characterisation and novel therapeutics, such as targeted radioisotopes and immunotherapy, hold promise for improving patient outcomes.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal